SciELO - Scientific Electronic Library Online

 
vol.38 suppl.1Contaminación por mercurio de leche materna de madres lactantes de municipios de Antioquia con explotación minera de oroVitamina D y riesgo de preeclampsia: revisión sistemática y metaanálisis índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Biomédica

versión impresa ISSN 0120-4157

Resumen

MANTILLA, Carolina et al. Molecular and clinical characterization of Colombian patients suffering from type III glycogen storage disease. Biomédica [online]. 2018, vol.38, suppl.1, pp.30-42. ISSN 0120-4157.  https://doi.org/10.7705/biomedica.v38i0.3454.

Introduction:

Type III glycogen storage disease (GSD III) is an autosomal recessive disorder in which a mutation in the AGL gene causes deficiency of the glycogen debranching enzyme. The disease is characterized by fasting hypoglycemia, hepatomegaly and progressive myopathy. Molecular analyses of AGL have indicated heterogeneity depending on ethnic groups. The full spectrum of AGL mutations in Colombia remains unclear.

Objective:

To describe the clinical and molecular characteristics of ten Colombian patients diagnosed with GSD III.

Materials and methods:

We recruited ten Colombian children with a clinical and biochemical diagnosis of GSD III to undergo genetic testing. The full coding exons and the relevant exon-intron boundaries of the AGL underwent Sanger sequencing to identify mutation.

Results:

All patients had the classic phenotype of the GSD III. Genetic analysis revealed a mutation p.Arg910X in two patients. One patient had the mutation p.Glu1072AspfsX36, and one case showed a compound heterozygosity with p.Arg910X and p.Glu1072AspfsX36 mutations. We also detected the deletion of AGL gene 3, 4, 5, and 6 exons in three patients. The in silico studies predicted that these defects are pathogenic. No mutations were detected in the amplified regions in three patients.

Conclusion:

We found mutations and deletions that explain the clinical phenotype of GSDIII patients. This is the first report with a description of the clinical phenotype and the spectrum of AGLmutations in Colombian patients. This is importantto provide appropriate prognosis and genetic counseling to the patient and their relatives.

Palabras clave : Glycogen storage disease type III/diagnosis; glycogen; glycogen debranching enzyme system; glycogenolysis.

        · resumen en Español     · texto en Español     · Español ( pdf )